Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Cefoxitin sodium may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Renoxitin is a beta-lactam antibiotic in the group of the second-generation cephalosporins. This medicine is indicated in adults and in adolescents for the treatment of infections when known or suspected to be caused by pathogens susceptible to cefoxitin. Renoxitin is indicated for: • complicated urinary tract infections • pyelonephritis Cefoxitin may have utility notably in intra-abdominal infections and some gynaecological infections. 2.
e Renoxitin
Do not use Renoxitin: if you are allergic to cefoxitin, to any other cephalosporin antibiotics or any of the other ingredients of this medicine (listed in section 6). if you have ever had a severe allergic (hypersensitive) reaction (e.g., severe skin peeling; swelling of the face, hands, feet, lips, tongue or throat; or difficulty swallowing or breathing) to any other type of betalactam antibiotic (penicillins, monobactams and carbapenems). Warnings and precautions Talk to your doctor, pharmacist or nurse before using Renoxitin. Allergic reactions Any signs of an allergic reaction (rash, itching…) during treatment should be immediately reported to your doctor. If a severe, sudden allergic reactions happens, the administration of Renoxitin will have to be stopped. Before you start this treatment, tell your doctor if you have ever developed hives or another type of rash, itching, Quincke's oedema (sudden swelling of the face and neck caused by an allergic reaction) during previous treatment with antibiotics.
2
Diarrhoea The occurrence of diarrhoea during antibiotic treatment should not be treated without medical advice. Diarrhoea may develop while you are taking antibiotics, including cefoxitin, or after you have stopped taking them. If it becomes severe or persistent or you notice that your stool contains blood or mucus, contact your doctor immediately, as this can be life-threatening. Do not take medicines that stop or slow down bowel movements. In case of doubt, talk to your doctor or pharmacist. Neurological disorders As with all antibiotics belonging to this therapeutic class, the administration of this medicinal product may lead to a risk of encephalopathy (which may result in confusion, disorders of consciousness, seizure, abnormal movements) and, particularly, in case of overdose or kidney dysfunction. If any of these appear, consult your doctor or pharmacist immediately (see sections 3 and 4). Kidney function Inform your doctor if you have kidney disease, because your dose may need to be adjusted. If you are taking other medicines that are harmful for your kidneys or if you use diuretics (water pills), your doctor will monitor your kidney function. Laboratory tests Some laboratory test results may be altered while you take this medicine. Other medicines and Renoxitin Tell your doctor if you are using, have recently used or might use any other medicines. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Pregnancy Renoxitin should be used during pregnancy only under medical advice. If you discover that you are pregnant while taking Renoxitin, consult your doctor who is the only person who can judge whether the drug should be continued. Breast-feeding Stop breast-feeding while you are using this medicine to avoid any allergic reactions in your baby. Driving and using machines Renoxitin has a major influence on the ability to drive and use machines especially because of the possible occurrence of encephalopathy (see sections 3 and 4). Renoxitin contains sodium. This medicinal product contains 50 mg of sodium (main component of cooking/table salt) per g. This is equivalent to 2,5% of the recommended maximum daily dietary intake of sodium for an adult. This should be taken into consideration if you are on a controlled-sodium diet.
3.
How to use Renoxitin
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Your doctor or other Healthcare professional will give you this medicine into one of your veins. Recommended dose
3
Your doctor will decide the dose that you need each day and how often the injections/infusions should be administered per day. The recommended dose may be: Adults and adolescents: 2g every 4- 6 hours to a maximum of 12g/ day. Patients with kidney problems If you have a kidney problem, your doctor may change your dose. Use in Children There are insufficient data to recommend a posology in children aged up to 11 years.
Renoxitin Cefoxitin may be administered by slow intravenous injection over a period of 3 to 5 minutes. A solution of this medicinal product may also be administered by continuous intravenous infusion. For instructions on reconstitution and dilution of the medicinal product before administration, see information intended for Healthcare professionals. If you use more Renoxitin than you should As with all antibiotics belonging to this therapeutic class, the administration of this medicinal product may lead to a risk of encephalopathy (which may result in confusion, disorders of consciousness, seizure, abnormal movements) and, particularly, in case of overdose or kidney dysfunction. If any of these appear, consult your doctor or pharmacist immediately (see sections 2 and 4). If you forget to use Renoxitin Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Not known (the frequency is not known):
4
–
Serious neurological disorders known as encephalopathy (which may result in confusion, disorders of consciousness, seizure, abnormal movements) and, particularly, in case of high doses or kidney dysfunction (see sections 2 and 3).
Reporting of side effects If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App. By reporting side effects, you can help provide more information on the safety of this medicine. 5.
Renoxitin
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month. This medicinal product does not require any special storage conditions. After reconstitution: Chemical and physical in-use stability has been demonstrated for 8 hours at 25°C and 2-8°C with Water for Injections. From a microbiological point of view, the product should be used immediately. If not used immediately, in use storage times and conditions are the responsibility of the user. After dilution of the reconstituted solution with the solvents: Do not refrigerate. Chemical and physical in-use stability has been demonstrated for 4 hours at 25 °C. From a microbiological point of view, unless the method of dilution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of user. Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
What Renoxitin contains –
The active substance is cefoxitin sodium. Each vial contains 1.0515 g of cefoxitin sodium equivalent to 1000 mg of cefoxitin. Each vial contains 2.103 g of cefoxitin sodium equivalent to 2000 mg of cefoxitin.
What Renoxitin looks like and contents of the pack Renoxitin is a white or almost white powder. Renoxitin is supplied in vials containing 1g or 2g of cefoxitin as the sodium salt, closed with chlorobutyl rubber stopper and sealed with an aluminium capsule with polypropylene flip-off. Renoxitin 1g Powder for solution for injection/infusion is available in packs of 1, 5, 10, 20, 25, 50 and 100 vials. Renoxitin 2g Powder for solution for injection/infusion is available in packs of 1, 5, 10, 20, 25, 50 and 100 vials. Not all pack sizes will be marketed. 5
Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder Renascience Pharma Limited The Urban Building Second Floor, 3-9 Albert Street, Slough, Berkshire, SL1 2BE, United Kingdom Manufacturer LDP- Laboratorios TORLAN, S.A. Ctra de Barcelona, 135 B 08290 Cerdanyola del Valles Barcelona – Spain This leaflet was last revised in 05/2025
————————————————————————————————————————–ADVICE/MEDICAL EDUCATION What should you know about antibiotics? Antibiotics are effective against infections caused by bacteria. They do not work against infections caused by viruses. Also, your doctor chose to prescribe this antibiotic for you because it suits your particular case and your current illness. Some bacteria have the ability to survive and reproduce despite the action of an antibiotic. This phenomenon is known as resistance: it inactivates certain antibiotic treatments. Resistance is the result of abusive or inappropriate use of antibiotics. You may promote the development of resistant bacteria and therefore delay your recovery or even inactivate this medicine, if you do not:
6
Cefoxitin may be reconstituted with 10 ml water for injections. Immediately after reconstitution, this Cefoxitin solution can be also added to 40 ml of the following solutions, frequently used in infusion(1g or 2g into 50 ml solution, corresponding to 20 to 40mg/ml):
7
Renoxitin 1g Powder for solution for injection or Infusion comes as injection containing 1g. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Renoxitin 1g Powder for solution for injection or Infusion is cefoxitin sodium.
This leaflet reproduces the patient information leaflet approved for Renoxitin 1g Powder for solution for injection or Infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Renoxitin is indicated in adults and adolescents,
Cefoxitin should only be prescribed after consultation with physicians with appropriate expertise in the treatment of infectious diseases.
Cefoxitin may be used in the following infections when known or suspected to be caused by pathogens susceptible to cefoxitin and for which other, more commonly prescribed antibacterial agents are not appropriate.
Renoxitin is indicated for:
• complicated urinary tract infections
• pyelonephritis
Cefoxitin may have utility notably in intra- abdominal infections and some gynaecological infections. Please see section 4.4 for special warnings and precautions.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Posology
There are very limited clinical safety and efficacy data supporting the dose of cefoxitin. Therapeutic guidelines should be adhered to.
Based on these very limited clinical data and some supporting pharmacokinetic/ pharmacodynamic data, the following may be appropriate:
Adults and adolescents:
2g every 4- 6 hours to a maximum of 12g/ day.
Renal impairment
There are extremely little data on the administration of cefoxitin in patients with renal impairment. Great caution is advised when cefoxitin is administered to these patients. In adults with renal impairment, an initial loading dose of 2 g can be administered. After the loading dose, the following recommendations can be used as guide for maintenance treatment:
Creatinine clearance (mL/min)
Dose
Frequency
50 - 30
2 g
Every 8 - 12 hours
29 - 10*
2 g
Every 12 - 24 hours
* In patients on haemodialysis, the loading dose of 2 g should be given after each haemodialysis, and the maintenance treatment should be given as indicated in the table above.
Paediatric population
There are insufficient data to recommend a posology in children aged up to 11 years.
Method of administration
Cefoxitin may be administered by slow intravenous injection over a period of 3 to 5 minutes.
A solution of this medicinal product may also be administered by continuous intravenous infusion.
For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.
Hypersensitivity to the active substance, to any other cephalosporin antibiotics or to any of the excipients listed in section 6.1.
History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta-lactam antibacterial agent (penicillins, monobactams and carbapenems).
Hypersensitivity reactions
As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with cefoxitin must be discontinued immediately and adequate emergency measures must be initiated.
Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to cefoxitin, to other cephalosporins or to any other type of beta-lactam antibacterial agent. Caution should be used if cefoxitin is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.
Clostridium difficile-associated diarrhoea
Antibiotic-associated colitis and pseudomembranous colitis have been reported with nearly all anti-bacterial agents and may occur with Cefoxitin (see section 4.8). These types of infection may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of the antibiotic. In such circumstances, the discontinuation of therapy with cefoxitin and the use of supportive measures together with the administration of specific treatment for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given.
Non-susceptible microorganisms
Prolonged use may result in the overgrowth of non-susceptible micro-organisms, which may require interruption of treatment or other appropriate measures.
Risk of encephalopathy
Beta-lactam antibiotics exposes to a risk of encephalopathy (confusion, disorders of consciousness, seizure, abnormal movements) and, particularly, in case of overdose or reduced renal function.
Impaired renal function
In patients with renal impairment, dosage adjustment should be based on the creatinine clearance and serum creatinine (see section 4.2).
Concurrent treatment with diuretics or aminoglycosides
Renal function should be monitored during treatment if cefoxitin is given in combination with other potentially nephrotoxic antibiotics (especially aminoglycosides), or with furosemide or etacrynic acid diuretics.
Bacterial meningitis
The use of cefoxitin in the treatment of meningitis is not substantiated by appropriate data. Therefore, cefoxitin is not indicated for the treatment of meningitis.
Important information about excipients
Renoxitin contains sodium.
This medicinal product contains 2.17 mmol (or 50 mg) of sodium, per g equivalent to 2,5% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
Interference with laboratory tests
• Coombs test: false-positive results have been observed during treatment with cephalosporins. This may also occur in patients treated with cefoxitin.
• Glycosuria: false-positive results may be observed with reduction substances, however, no interaction has been observed with enzymatic methods.
• Jaffe (picric acid) serum creatinine test may show falsely high creatinine values. This may occur if cefoxitin serum concentrations exceed 100 mcg/ml.
Do not perform this assay on serum samples taken less than 2 hours after administration of Renoxitin.
• Urinary 17-hydroxy-corticosteroid: Porter Silber reaction may give moderate, falsely increased results in patients with high urinary concentrations of cefoxitin.
Problems specific to uncontrolled INR
There are numerous reports of potentiation of oral anticoagulant activity in patients on antibiotic therapy. The infectious or inflammatory disease background, the age and general condition of the patient appear to be risk factors. In these circumstances, it can be difficult to establish whether the infectious pathology or its treatment has caused the uncontrolled INR. However, certain classes of antibiotics are more involved, including fluoroquinolones, macrolides, tetracyclines, cotrimoxazole and certain cephalosporins.
Pregnancy
Animal studies have not shown evidence of a teratogenic effect. As teratogenic effects have not been observed in animals, malformations are not expected in humans. To date, substances that have been found to cause malformations in humans have been shown to be teratogenic in animals during well-controlled studies on two animal species.
A large amount of clinical data on pregnant women indicate no malformative nor feto/neonatal toxicity of cefoxitin. Nevertheless, epidemiological studies would be required to verify the absence of risk.
Renoxitin should therefore only be used during pregnancy if clinically needed.
Breast-feeding
Cefoxitin is excreted in human milk.
Breast-feeding should be discontinued during administration of Renoxitin to prevent any allergic reactions in the infant.
Renoxitin has a major influence on the ability to drive and use machines especially because of the possible occurrence of encephalopathy (see sections 4.4, 4.8 and 4.9).
Undesirable effects are classified by frequency and system organ class. The following terminologies have been used in order to classify the occurrence of undesirable effects: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1.000 to <1/100), rare (≥1/10.000 to <1/1.000), very rare (<1/10.000), not known (cannot be estimated from the available data).
System organ class
Frequency of undesirable effects
Frequency not known
Immune system disorders
Anaphylactic reaction
Blood and lymphatic system disorders
Eosinophilia
Leukopenia
Neutropenia (agranulocytosis)
Anaemia (including haemolytic anaemia)
Thrombocytopenia
Bone marrow failure
Vascular disorders
Local thrombophlebitis after intravenous administration
Gastrointestinal disorders
Nausea
Vomiting
Diarrhoea
Pseudomembranous colitis
Nervous system disorders
Encephalopathy (confusion, disorders of consciousness, seizure, abnormal movements)*
Hepatobiliary disorders
Transaminases increased
Blood lactate dehydrogenase increased
Blood alkaline phosphatase increased
Skin and subcutaneous tissue disorders
Rash
Urticaria
Pruritus
Toxic epidermal necrolysis
Angioedema
Musculoskeletal and connective tissue disorders
Myasthenia gravis exacerbation
Renal and urinary disorders
Nephritis interstitial
Blood creatinine increased and/or BUN increased (especially in combination therapy with aminoglycosides and loop diuretics)
Severe renal impairment
General disorders and administration site conditions
Pyrexia
Local reaction
* Βeta-lactam antibiotics expose to a risk of encephalopathy (confusion, disorders of consciousness, seizure, abnormal movements) and, particularly, in case of overdose or reduced renal function.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in appendix V.
Beta-lactam antibiotics exposes to a risk of encephalopathy (confusion, disorders of consciousness, seizure, abnormal movements) and, particularly, in case of overdose or reduced renal function.
Ask anything about Renoxitin 1g Powder for solution for injection or Infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.